These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10372579)

  • 1. The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients.
    Cowen ME; Miles BJ; Cahill DF; Giesler RB; Beck JR; Kattan MW
    Med Decis Making; 1998; 18(4):376-80. PubMed ID: 10372579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.
    Sommers BD; Beard CJ; D'Amico AV; Dahl D; Kaplan I; Richie JP; Zeckhauser RJ
    Cancer; 2007 Nov; 110(10):2210-7. PubMed ID: 17893907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of a utilities-based treatment decision intervention for prostate cancer patients.
    Knight SJ; Nathan DP; Siston AK; Kattan MW; Elstein AS; Collela KM; Wolf MS; Slimack NS; Bennett CL; Golub RM
    Clin Prostate Cancer; 2002 Sep; 1(2):105-14. PubMed ID: 15046701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preference assessment method affects decision-analytic recommendations: a prostate cancer treatment example.
    Elkin EB; Cowen ME; Cahill D; Steffel M; Kattan MW
    Med Decis Making; 2004; 24(5):504-10. PubMed ID: 15358999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating preferences for treatments in patients with localized prostate cancer.
    Ávila M; Becerra V; Guedea F; Suárez JF; Fernandez P; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Cunillera O; Pardo Y; Cots F; Ferrer M;
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):277-87. PubMed ID: 25491504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team.
    Fleming C; Wasson JH; Albertsen PC; Barry MJ; Wennberg JE
    JAMA; 1993 May; 269(20):2650-8. PubMed ID: 8487449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do older men benefit from curative therapy of localized prostate cancer?
    Alibhai SM; Naglie G; Nam R; Trachtenberg J; Krahn MD
    J Clin Oncol; 2003 Sep; 21(17):3318-27. PubMed ID: 12947068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid.
    van Tol-Geerdink JJ; Willem Leer J; Weijerman PC; van Oort IM; Vergunst H; van Lin EN; Alfred Witjes J; Stalmeier PF
    BJU Int; 2013 Apr; 111(4):564-73. PubMed ID: 22882966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer screening: a decision analysis.
    Cantor SB; Spann SJ; Volk RJ; Cardenas MP; Warren MM
    J Fam Pract; 1995 Jul; 41(1):33-41. PubMed ID: 7798064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis.
    Parikh R; Sher DJ
    Cancer; 2012 Jan; 118(1):258-67. PubMed ID: 21720990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A decision support model for cost-effectiveness of radical prostatectomy in localized prostate cancer.
    Lyth J; Andersson SO; Andrén O; Johansson JE; Carlsson P; Shahsavar N
    Scand J Urol Nephrol; 2012 Feb; 46(1):19-25. PubMed ID: 21905981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
    Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
    Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis.
    Mold JW; Holtgrave DR; Bisonni RS; Marley DS; Wright RA; Spann SJ
    J Fam Pract; 1992 May; 34(5):561-8. PubMed ID: 1578205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient preferences for outcomes associated with surgical management of prostate cancer.
    Smith DS; Krygiel J; Nease RF; Sumner W; Catalona WJ
    J Urol; 2002 May; 167(5):2117-22. PubMed ID: 11956454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer.
    Reed SD; Stewart SB; Scales CD; Moul JW
    Value Health; 2014 Jul; 17(5):545-54. PubMed ID: 25128047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.
    Sanyal C; Aprikian AG; Cury FL; Chevalier S; Dragomir A
    Cancer; 2016 Apr; 122(7):1085-96. PubMed ID: 26828716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of localized prostatic cancer--different alternatives. Patients with localized prostatic cancer must actively participate in the choice of therapy].
    Adolfsson J
    Lakartidningen; 2000 Sep; 97(36):3870-4. PubMed ID: 11036336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer staging: should MR imaging be used?--A decision analytic approach.
    Jager GJ; Severens JL; Thornbury JR; de La Rosette JJ; Ruijs SH; Barentsz JO
    Radiology; 2000 May; 215(2):445-51. PubMed ID: 10796923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.
    Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Ruutu M; Bill-Axelson A;
    Lancet Oncol; 2011 Sep; 12(9):891-9. PubMed ID: 21821474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.
    Bratt O; Folkvaljon Y; Hjälm Eriksson M; Akre O; Carlsson S; Drevin L; Franck Lissbrant I; Makarov D; Loeb S; Stattin P
    Eur Urol; 2015 Jul; 68(1):53-8. PubMed ID: 25813688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.